Monash University and The Alfred Hospital researchers have developed a tailored bacteriophage therapy cocktail, Entelli-02, specifically targeting antimicrobial-resistant pathogens. This phage-based treatment offers a novel weapon against bacteria resistant to conventional antibiotics, addressing a critical global health threat. Concurrent work includes a bespoke phage cocktail for Enterobacter cloacae infections, optimizing virus-mediated bacterial eradication. These advances promise targeted, effective options for difficult-to-treat infections, reducing reliance on traditional antimicrobials and mitigating resistance development.